Bristol Myers (BMY) “Hold” Rating Reiterated by Analysts at Cowen & Co.; With $60.0000 Target; Van Den Berg Management I Has Decreased Lydall Del (LDL) Position

April 20, 2018 - By Maria Brooks

Bristol-Myers Squibb Company (NYSE:BMY) Logo

Van Den Berg Management I Inc decreased Lydall Inc Del (LDL) stake by 34.95% reported in 2017Q4 SEC filing. Van Den Berg Management I Inc sold 7,200 shares as Lydall Inc Del (LDL)’s stock declined 7.70%. The Van Den Berg Management I Inc holds 13,400 shares with $680,000 value, down from 20,600 last quarter. Lydall Inc Del now has $839.05 million valuation. The stock decreased 1.83% or $0.9 during the last trading session, reaching $48.35. About 43,370 shares traded. Lydall, Inc. (NYSE:LDL) has declined 8.60% since April 20, 2017 and is downtrending. It has underperformed by 20.15% the S&P500.

Bristol Myers (NYSE:BMY) had its stock rating noted as “Hold” by analysts at Cowen & Co.. Cowen & Co. currently has a $60.0000 PT on the $84.38B market cap company or 16.26% upside potential. This was disclosed to clients in a research report on Friday morning.

Since December 12, 2017, it had 1 buy, and 1 sale for $85,985 activity. Another trade for 4,000 shares valued at $249,187 was made by Samuels Theodore R. II on Friday, December 15. Lynch Thomas J. Jr. sold $335,172 worth of stock or 5,300 shares.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on April, 26 before the open. They expect $0.84 EPS, 0.00% or $0.00 from last year’s $0.84 per share. BMY’s profit will be $1.37B for 15.36 P/E if the $0.84 EPS becomes a reality. After $0.68 actual EPS reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts 23.53% EPS growth.

The stock decreased 1.32% or $0.69 during the last trading session, reaching $51.61. About 17.15 million shares traded or 93.93% up from the average. Bristol-Myers Squibb Company (NYSE:BMY) has risen 11.37% since April 20, 2017 and is uptrending. It has underperformed by 0.18% the S&P500.

Investors sentiment decreased to 0.94 in Q4 2017. Its down 0.09, from 1.03 in 2017Q3. It dived, as 72 investors sold Bristol-Myers Squibb Company shares while 526 reduced holdings. 106 funds opened positions while 457 raised stakes. 1.11 billion shares or 0.48% more from 1.11 billion shares in 2017Q3 were reported. Svcs Corporation reported 11,625 shares. Sumitomo Life Ins owns 52,430 shares for 0.4% of their portfolio. Aureus Asset Mngmt stated it has 201,390 shares. Balyasny Asset Management Ltd Liability Corp invested 0.21% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Liberty Capital Mngmt Inc owns 1,400 shares. Virtus Advisers Incorporated holds 0.05% in Bristol-Myers Squibb Company (NYSE:BMY) or 33,873 shares. Hillsdale Invest Management owns 5,840 shares. Loomis Sayles L P holds 1.72% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 13.51M shares. Hutchinson Mgmt Ca reported 3,780 shares. Illinois-based First Amer Bancorporation has invested 0.12% in Bristol-Myers Squibb Company (NYSE:BMY). Mark Sheptoff Financial Planning Limited Liability Corporation holds 1.66% in Bristol-Myers Squibb Company (NYSE:BMY) or 41,667 shares. Dynamic Solutions Ltd Liability owns 16,723 shares or 0.34% of their US portfolio. Dnb Asset Mngmt As, a Norway-based fund reported 367,362 shares. Marble Harbor Investment Counsel Limited Liability invested in 0.09% or 7,617 shares. Elm Limited Liability Corporation owns 0.3% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 6,583 shares.

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide. The company has market cap of $84.38 billion. The firm offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection . It has a 84.61 P/E ratio. The Company’s products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

Among 22 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 7 have Buy rating, 3 Sell and 12 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company has $80 highest and $45 lowest target. $64.18’s average target is 24.36% above currents $51.61 stock price. Bristol-Myers Squibb Company had 80 analyst reports since July 28, 2015 according to SRatingsIntel. As per Thursday, October 19, the company rating was maintained by Cowen & Co. On Monday, August 24 the stock rating was upgraded by Piper Jaffray to “Underweight”. The company was maintained on Monday, July 17 by Deutsche Bank. The firm has “Buy” rating given on Wednesday, October 18 by Citigroup. The stock has “Buy” rating by Citigroup on Friday, February 16. As per Friday, April 13, the company rating was maintained by Jefferies. The company was maintained on Monday, August 14 by Cowen & Co. Barclays Capital maintained Bristol-Myers Squibb Company (NYSE:BMY) on Friday, April 29 with “Equal Weight” rating. Piper Jaffray maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Friday, September 22. Piper Jaffray has “Hold” rating and $60.0 target. The firm has “Hold” rating given on Monday, July 10 by Cowen & Co.

Van Den Berg Management I Inc increased Colfax Corp (NYSE:CFX) stake by 76,484 shares to 1.16 million valued at $46.10 million in 2017Q4. It also upped Pioneer Energy Svcs Corp (NYSE:PES) stake by 596,900 shares and now owns 7.52 million shares. Transocean Ltd (NYSE:RIG) was raised too.

Analysts await Lydall, Inc. (NYSE:LDL) to report earnings on May, 1. They expect $0.65 earnings per share, down 12.16% or $0.09 from last year’s $0.74 per share. LDL’s profit will be $11.28M for 18.60 P/E if the $0.65 EPS becomes a reality. After $0.67 actual earnings per share reported by Lydall, Inc. for the previous quarter, Wall Street now forecasts -2.99% negative EPS growth.

Among 3 analysts covering Lydall (NYSE:LDL), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Lydall had 7 analyst reports since August 29, 2016 according to SRatingsIntel. Roth Capital maintained Lydall, Inc. (NYSE:LDL) on Monday, February 26 with “Buy” rating. The stock has “Buy” rating by TH Capital on Wednesday, November 9. Sidoti upgraded the stock to “Buy” rating in Wednesday, September 13 report. On Monday, June 26 the stock rating was maintained by Roth Capital with “Buy”. The stock of Lydall, Inc. (NYSE:LDL) has “Buy” rating given on Wednesday, November 9 by Roth Capital. The firm has “Neutral” rating given on Monday, August 29 by Sidoti. Roth Capital maintained it with “Buy” rating and $6300 target in Monday, July 31 report.

Investors sentiment decreased to 1.4 in 2017 Q4. Its down 0.01, from 1.41 in 2017Q3. It fall, as 10 investors sold LDL shares while 42 reduced holdings. 23 funds opened positions while 50 raised stakes. 15.36 million shares or 1.51% more from 15.13 million shares in 2017Q3 were reported. Swiss Fincl Bank has 0% invested in Lydall, Inc. (NYSE:LDL). Royal Commercial Bank Of Canada invested 0.02% of its portfolio in Lydall, Inc. (NYSE:LDL). Meeder Asset Mgmt owns 411 shares. Dimensional Fund Advisors Lp accumulated 1.01M shares. Victory Capital Management Inc has invested 0% of its portfolio in Lydall, Inc. (NYSE:LDL). Us Bank & Trust De accumulated 39,967 shares. Sei invested in 0.01% or 54,185 shares. Salzhauer Michael has invested 0.1% of its portfolio in Lydall, Inc. (NYSE:LDL). Jefferies Gp Limited Liability Company has 2,253 shares for 0% of their portfolio. Raymond James And Associate reported 4,187 shares. Teachers Retirement Systems Of The State Of Kentucky stated it has 0% in Lydall, Inc. (NYSE:LDL). Millennium Mngmt Limited Com holds 137,683 shares or 0.01% of its portfolio. Century Inc has 49,695 shares. State Of Tennessee Treasury Department holds 0% or 13,607 shares. Atlantic Tru Limited Liability Company has invested 0% in Lydall, Inc. (NYSE:LDL).

Since March 8, 2018, it had 0 insider buys, and 4 insider sales for $897,338 activity. 2,050 shares were sold by Abbruzzi Joseph A., worth $100,450. DEAKIN SCOTT M sold $242,100 worth of stock. 7,604 shares valued at $378,708 were sold by BURDETT KATHLEEN on Monday, March 12.

Lydall, Inc. (NYSE:LDL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts